Valued at USD 17.68 billion in 2025, the leukemia therapeutics market is projected to reach USD 18.82 billion in 2026 and USD 31.43 billion by 2034, growing at a CAGR of 6.6% during the forecast period 2026–2034. Rising leukemia prevalence, stronger oncology research investment and the shift toward personalized, biomarker-guided care are reshaping how therapies are developed, delivered and reimbursed across regions.

Chemotherapy Retains a Significant Share

By treatment type, the leukemia therapeutics market is segmented into chemotherapy and targeted drug therapy. Chemotherapy holds a significant share because of its long-standing use as a standard treatment for various leukemia types. It remains important in induction therapy, salvage settings and combination regimens, especially in severe cases and acute leukemias, even as innovation shifts toward personalized care and targeted drug therapy is projected to grow more rapidly.

Acute Myeloid Leukemia and Mutation-Targeted Care

Within type segmentation, acute myeloid leukemia is fueling fast growth through increasing use of mutation-based treatments and continued innovation. FLT3 inhibitors and IDH inhibitors are reshaping care in this segment. In June 2025, Johnson & Johnson announced positive phase 1b results for bleximenib combined with venetoclax and azacitidine in KMT2A- and NPM1-mutated acute myeloid leukemia, signaling progress in mutation-targeting therapies within the pipeline. These options enable precision medicine in relapsed patients.

Browse Insights:

https://www.polarismarketresearch.com/industry-analysis/global-leukemia-therapeutics-market

Next-Generation Sequencing in Treatment Strategies

Next-generation sequencing is increasingly used in leukemia treatment, enabling detailed genomic analysis of leukemia subtypes. It identifies key mutations such as BCR-ABL or NPM1, which guide the selection of targeted treatments, and supports molecular profiling, early mutation detection, risk assessment and therapy adjustment for resistance. Falling costs are making sequencing routine, boosting outcomes and adoption of targeted drugs across leukemia types while strengthening the leukemia diagnostics market. Better risk assessment follows from this molecular insight, aiding therapy decisions when resistance emerges.

Small Molecules and Biologics

By molecule type, small molecules hold the largest share. This dominance is fueled by widespread use of small molecule inhibitors, mainly tyrosine kinase inhibitors, for chronic myeloid leukemia and other subtypes, as well as oral availability, strong physician familiarity and cost-effective manufacturing. Biologics, including monoclonal antibodies and cell therapy products, are expanding quickly as they play a major role in advanced therapies, highlighting differences in pricing, manufacturing complexity, treatment settings and competitive positioning. Together, these molecule classes create differences in treatment settings that manufacturers must address.

Mode of Administration and Gender Segmentation

The oral segment holds the largest share by mode of administration, supported by convenience, ease of administration and improved compliance, and by its role in outpatient, long-term disease management. Injectable products are expected to grow faster because of advanced therapies requiring close hospital monitoring. By gender, the male segment holds the largest share, attributed to higher leukemia incidence among males, though improving female diagnosis and access are expected to increase treatment rates.

Competitive Landscape

Competition is fueled by strong targeted therapy portfolios, growing immunotherapy pipelines and strategic collaborations. Key players include Novartis AG, Pfizer Inc., Amgen Inc., Roche Holding AG, Bristol Myers Squibb, Gilead Sciences Inc., AbbVie Inc., AstraZeneca, Takeda Pharmaceutical Company Limited, Sanofi, Eli Lilly and Company, Merck & Co., Inc., Celgene Corporation, Incyte Corporation and Kite Pharma. Novartis is known for imatinib (Gleevec), and Pfizer for bosutinib (Bosulif) in chronic myeloid leukemia. Oncology licensing deals are helping accelerate development and market entry. Companies with strong immunotherapy and targeted therapy capabilities are likely to gain an advantage, supported by clinical trials, label expansions and partnerships with biotech firms.

Restraints and Outlook

Side effects and detrimental reactions impede market growth. Even so, government funding and initiatives that enhance oncology care worldwide, together with expanding adoption of precision medicine, support long-term momentum, with Asia Pacific identified as the fastest-growing region and North America as the largest market. Leukemia therapeutics drug approvals for mutation-specific options and growing CAR-T use in difficult cases support commercial growth.

More Trending Latest Reports By Polaris Market Research:

cyber-security-market

analyzing-top-20-companies-driving-growth-in-the-drone-delivery-market-in-2025

enhanced-due-diligence-market

oral-care-market

lentiviral-vector-market

strobilurin-fungicide-market

us-mens-jewelry-market

mdi-manufacturers

truck-and-bus-radial-tire-market